» Articles » PMID: 35269713

Non-Invasive Profiling of Advanced Prostate Cancer Via Multi-Parametric Liquid Biopsy and Radiomic Analysis

Abstract

Integrating liquid biopsies of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) with other minimally invasive measures may yield more comprehensive disease profiles. We evaluated the feasibility of concurrent cellular and molecular analysis of CTCs and cfDNA combined with radiomic analysis of CT scans from patients with metastatic castration-resistant PC (mCRPC). CTCs from 22 patients were enumerated, stained for PC-relevant markers, and clustered based on morphometric and immunofluorescent features using machine learning. DNA from single CTCs, matched cfDNA, and buffy coats was sequenced using a targeted amplicon cancer hotspot panel. Radiomic analysis was performed on bone metastases identified on CT scans from the same patients. CTCs were detected in 77% of patients and clustered reproducibly. cfDNA sequencing had high sensitivity (98.8%) for germline variants compared to WBC. Shared and unique somatic variants in PC-related genes were detected in cfDNA in 45% of patients (MAF > 0.1%) and in CTCs in 92% of patients (MAF > 10%). Radiomic analysis identified a signature that strongly correlated with CTC count and plasma cfDNA level. Integration of cellular, molecular, and radiomic data in a multi-parametric approach is feasible, yielding complementary profiles that may enable more comprehensive non-invasive disease modeling and prediction.

Citing Articles

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J JAMA Netw Open. 2024; 7(10):e2437871.

PMID: 39374015 PMC: 11581504. DOI: 10.1001/jamanetworkopen.2024.37871.


Radiogenomics: bridging the gap between imaging and genomics for precision oncology.

He W, Huang W, Zhang L, Wu X, Zhang S, Zhang B MedComm (2020). 2024; 5(9):e722.

PMID: 39252824 PMC: 11381657. DOI: 10.1002/mco2.722.


Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction.

Ying M, Mao J, Sheng L, Wu H, Bai G, Zhong Z J Pers Med. 2023; 13(5).

PMID: 37240875 PMC: 10219132. DOI: 10.3390/jpm13050705.


Predicting Extrathyroidal Extension in Papillary Thyroid Carcinoma Using a Clinical-Radiomics Nomogram Based on B-Mode and Contrast-Enhanced Ultrasound.

Jiang L, Guo S, Zhao Y, Cheng Z, Zhong X, Zhou P Diagnostics (Basel). 2023; 13(10).

PMID: 37238217 PMC: 10217699. DOI: 10.3390/diagnostics13101734.


Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging.

Yeo D, Kao S, Gupta R, Wahlroos S, Bastian A, Strauss H Front Oncol. 2023; 13:1141228.

PMID: 37051527 PMC: 10083432. DOI: 10.3389/fonc.2023.1141228.


References
1.
Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T . SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011; 29(18):2565-73. PMC: 3138634. DOI: 10.1200/JCO.2010.31.2405. View

2.
Fraser M, Sabelnykova V, Yamaguchi T, Heisler L, Livingstone J, Huang V . Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017; 541(7637):359-364. DOI: 10.1038/nature20788. View

3.
Gerratana L, Davis A, Zhang Q, Basile D, Rossi G, Strickland K . Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer. JCO Precis Oncol. 2021; 5:943-952. PMC: 8202557. DOI: 10.1200/PO.20.00345. View

4.
Hodara E, Morrison G, Cunha A, Zainfeld D, Xu T, Xu Y . Multiparametric liquid biopsy analysis in metastatic prostate cancer. JCI Insight. 2019; 4(5). PMC: 6483502. DOI: 10.1172/jci.insight.125529. View

5.
Gerdtsson E, Pore M, Thiele J, Gerdtsson A, Malihi P, Nevarez R . Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry. Converg Sci Phys Oncol. 2019; 4(1). PMC: 6430142. DOI: 10.1088/2057-1739/aaa013. View